BindingDB

The first public molecular recognition database, BindingDB supports research, education and practice in drug discovery, pharmacology and related fields.

BindingDB contains 3.2M data for 1.4M Compounds and 11.4K Targets. Of those, 1.6M data for 756K Compounds and 4.8K Targets were curated by BindingDB curators. BindingDB is a FAIRsharing resource.

If BindingDB was of value to your research, please take a moment to donate to this nonprofit project. Your donation will let us provide you with more data and improved service.

Donate Now

To help with training and testing AI and other models, BindingDB downloads and search results now provide the publication date and BindingDB curation date of each measurement.

Advanced Search

20 articles for JT Link

The following articles (labelled with PubMed ID or TBD) are for your review

PMID
Data
Article Title
Organization
Liver-selective glucocorticoid antagonists: a novel treatment for type 2 diabetes.EBI
Abbott Laboratories
Bile acid conjugates of a nonsteroidal glucocorticoid receptor modulator.EBI
Abbott Laboratories
Synthesis, activity, metabolic stability, and pharmacokinetics of glucocorticoid receptor modulator-statin hybrids.EBI
Abbott Laboratories
An evaluation of a C-glucuronide as a liver targeting group: conjugate of a glucocorticoid antagonist.EBI
Abbott Laboratories
Discovery and metabolic stabilization of potent and selective 2-amino-N-(adamant-2-yl) acetamide 11beta-hydroxysteroid dehydrogenase type 1 inhibitors.EBI
Abbott Laboratories
Adamantane sulfone and sulfonamide 11-beta-HSD1 Inhibitors.EBI
Abbott Laboratories
Discovery of potent and selective inhibitors of 11beta-HSD1 for the treatment of metabolic syndrome.EBI
Abbott Laboratories
Adamantane 11-beta-HSD-1 inhibitors: Application of an isocyanide multicomponent reaction.EBI
Abbott Laboratories
Discovery of orally active butyrolactam 11beta-HSD1 inhibitors.EBI
Abbott Laboratories
Synthesis and biological evaluation of heterocycle containing adamantane 11beta-HSD1 inhibitors.EBI
Abbott Laboratories
Synthesis and structural activity relationship of 11beta-HSD1 inhibitors with novel adamantane replacements.EBI
Abbott Laboratories
Optimization and metabolic stabilization of a class of nonsteroidal glucocorticoid modulators.EBI
Abbott Laboratories
Discovery of novel nonsteroidal glucocorticoid receptor modulators.EBI
Abbott Laboratories
Biaryl amide glucagon receptor antagonists.EBI
Abbott Laboratories
Discovery of potent antagonists of leukocyte function-associated antigen-1/intercellular adhesion molecule-1 interaction. 3. Amide (C-ring) structure-activity relationship and improvement of overall properties of arylthio cinnamides.EBI
Abbott Laboratories
Discovery and SAR of diarylsulfide cyclopropylamide LFA-1/ICAM-1 interaction antagonists.EBI
Abbott Laboratories
Discovery of novel p-arylthio cinnamides as antagonists of leukocyte function-associated antigen-1/intracellular adhesion molecule-1 interaction. 1. Identification of an additional binding pocket based on an anilino diaryl sulfide lead.EBI
Abbott Laboratories
Heterocyclylalkyne derivatives and their use as modulators of mGluR5 receptorsBDB
Recordati Ireland
Discovery of 5-[5-fluoro-2-oxo-1,2- dihydroindol-(3Z)-ylidenemethyl]-2,4- dimethyl-1H-pyrrole-3-carboxylic acid (2-diethylaminoethyl)amide, a novel tyrosine kinase inhibitor targeting vascular endothelial and platelet-derived growth factor receptor tyrosine kinase.BDB
Sugen